Colletotrichum gloeosporioides infection detection method
A diagnostic method for anthrax infections using specific protocols improves early diagnosis, reduces transmission, and enhances treatment effectiveness by accurately classifying and detecting anthrax types.
Patent Information
- Application Number
- CN202410646656.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-23
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods are inadequate for rapid and accurate classification and detection of different anthrax infections, which hinders early diagnosis, increases transmission risk, and affects treatment efficacy.
A method comprising specific diagnostic protocols for cutaneous, inhalation, and mixed anthrax infections, including Gram staining, skin lesion culture, blood culture, symptom assessment, isolation, and advanced testing such as CT scans and PCR, to classify and detect anthrax infections accurately.
Enhances early diagnosis, reduces transmission risk, guides effective treatment plans, and improves patient survival and cure rates by providing timely and accurate detection and monitoring.
Smart Images

Figure CN119074037A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of anthrax bacteria infection detection, and in particular to a method for detecting anthrax bacteria infection. Background Art
[0002] Anthrax is an infection caused by Bacillus anthracis. Due to the latent infection characteristics of anthrax, it is impossible to simply classify and detect different anthrax infections based on symptoms. There is an urgent need for a rapid and accurate molecular detection method. To this end, it is urgent to propose an anthrax infection detection method to classify and detect different anthrax infections, help improve the early diagnosis rate of the disease, reduce the risk of transmission, and improve the cure rate and survival rate of patients. Summary of the invention
[0003] The purpose of this section is to summarize some aspects of the embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the specification abstract and the invention title of this application to avoid blurring the purpose of this section, the specification abstract and the invention title, and such simplifications or omissions cannot be used to limit the scope of the present invention.
[0004] Therefore, the purpose of the present invention is to provide a method for detecting anthrax infection, which can classify and detect different anthrax infections, and can help improve the early diagnosis rate of the disease, reduce the risk of transmission, guide treatment plans, and monitor treatment effects, which is helpful to improve the cure rate and survival rate of patients.
[0005] To solve the above technical problems, according to one aspect of the present invention, the present invention provides the following technical solutions: a method for detecting anthrax infection, which includes three anthrax infection detection methods:
[0006] (1) Cutaneous anthrax:
[0007] (2) Inhalation anthrax;
[0008] (3) Mixed anthrax.
[0009] As a preferred embodiment of the method for detecting anthrax infection described in the present invention, the method for detecting skin anthrax is as follows:
[0010] A1. Gram staining and skin lesion culture, plus blood culture, to determine whether the casualty has been attacked by cutaneous anthrax;
[0011] A2. Once eschar is present on the skin or the test result in step A1 is positive, the casualty shall be given antimicrobial treatment;
[0012] A3: If the culture in step A1 is negative and the papule has not progressed to eschar, cutaneous anthrax is unlikely.
[0013] A4. However, if the casualty is known or suspected to have been aerosol exposed to B. anthracis, inhalation anthrax prophylaxis should be continued for 60 days.
[0014] As a preferred embodiment of the method for detecting anthrax infection described in the present invention, the inhalation anthrax detection method is as follows:
[0015] S1. Group the injured according to whether they have symptoms;
[0016] S2. The injured patients will be further isolated in groups to prevent cross infection;
[0017] S3, grouping the injured persons isolated in step S2;
[0018] S4, dividing the groups in step S3 into two groups: those who need to be sent to the hospital for further examination, and those who need to take preventive antibiotics at home and wait for follow-up guidance;
[0019] S5. Further testing is performed on the two groups of injured persons in step S4 through medical institutions.
[0020] As a preferred embodiment of the method for detecting anthrax infection described in the present invention, the symptoms in step S1 include the presence or absence of headache, neurological symptoms, fever, cough, dyspnea, nausea or vomiting, abnormal lung examination, rhinorrhoea or sore throat and the like.
[0021] As a preferred embodiment of the method for detecting anthrax infection described in the present invention, the hybrid anthrax detection method is as follows:
[0022] N1. Quantify the physiological indicators of the injured and divide them into three categories according to the values;
[0023] N2, the first page of examination can classify the casualty into three categories: those who need immediate IV Rx treatment, those who need PO Rx / PEP treatment, and those who need medical evaluation and symptom assessment;
[0024] N3. Use the second page of the form for the injured who need medical evaluation according to step N2;
[0025] N4. The table on page 2 classifies the casualties into three categories: those who need IVRx treatment, those who need PORx / PEP treatment, and those who need diagnostic testing, based on whether the casualties have anthrax symptoms.
[0026] N5. The screening checklist combines easily collected vital sign data with brief questions about psychological function and symptoms, and is based on a physical examination consisting of observation of skin lesions, auscultation of the lungs, and assessment of ascites.
[0027] As a preferred embodiment of the method for detecting anthrax infection of the present invention, the detection in step S5 comprises the following steps:
[0028] S101. First, check whether the high-risk casualties with a history of exposure have non-specific symptoms of the first stage;
[0029] S102. If no symptoms occur, continue to observe. If exposure is confirmed and asymptomatic, perform antimicrobial prophylaxis;
[0030] S103. If the first stage symptoms occur, the injured person shall be examined by white blood cell count, chest radiograph, blood culture, CT, etc.;
[0031] S104. According to the examination results, the injured are divided into two groups: one with normal examination results and one with abnormal examination results, and different treatment measures are taken for the two groups of injured.
[0032] As a preferred embodiment of the method for detecting anthrax infection described in the present invention, wherein: in step N4, the diagnostic test includes ultrasound, X-ray photography and / or computed tomography of the chest and / or abdomen, or Gram staining or culture of pleural effusion, ascites, cerebrospinal fluid or wound or blood culture, or polymerase chain reaction serology of clinical specimens in a sterile location, or other Food and Drug Administration approved methods for identifying Bacillus anthracis.
[0033] Compared with the prior art, the present invention has the following beneficial effects:
[0034] It can classify and detect different anthrax bacteria infections and has the following benefits:
[0035] Early diagnosis: Cutaneous anthrax is a skin infection caused by Bacillus anthracis. Early detection can detect the disease in its early stages, making it easier to treat and reducing the severity of the disease and the occurrence of complications;
[0036] Preventing transmission: Through testing, patients can be found in time, measures can be taken to block the transmission pathways of pathogens, and the spread of diseases among the population can be avoided, which is helpful for the management and control of public health;
[0037] Guide treatment: The treatment plan for cutaneous anthrax varies depending on the severity of the disease and the site of infection. Through testing, doctors can more accurately assess the condition, develop an appropriate treatment plan, and improve treatment effectiveness;
[0038] Monitoring efficacy: During treatment, regular testing can help doctors monitor the effectiveness of treatment and adjust treatment plans in a timely manner to ensure that the condition is under control and improved;
[0039] In general, skin anthrax testing can help improve the early diagnosis rate of the disease, reduce the risk of transmission, guide treatment plans, and monitor treatment effectiveness, helping to improve patients' cure and survival rates. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the present invention will be described in detail below in combination with the accompanying drawings and detailed embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:
[0041] Figure 1 This is a schematic diagram of the steps for detecting skin anthrax of the present invention;
[0042] Figure 2 This is a schematic diagram of the inhalation anthrax detection steps of the present invention;
[0043] Figure 3 A schematic diagram of the steps of hybrid anthrax detection of the present invention;
[0044] Figure 4 This is a flow chart of skin anthrax detection of the present invention;
[0045] Figure 5 This is a flow chart of inhalation anthrax detection of the present invention;
[0046] Figure 6 The present invention is a flow chart for detecting casualties exposed to inhalation anthrax. DETAILED DESCRIPTION
[0047] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.
[0048] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.
[0049] Secondly, the present invention is described in detail with reference to schematic diagrams. When describing the embodiments of the present invention in detail, for the sake of convenience, the cross-sectional diagrams showing the device structure will not be partially enlarged according to the general scale, and the schematic diagrams are only examples, which should not limit the scope of protection of the present invention. In addition, in actual production, the three-dimensional dimensions of length, width and depth should be included.
[0050] In order to make the objectives, technical solutions and advantages of the present invention more clear, the embodiments of the present invention will be further described in detail below with reference to the accompanying drawings.
[0051] The present invention provides a method for detecting anthrax infection. Figure 1-3 , including three anthrax infection tests:
[0052] (1) Cutaneous anthrax:
[0053] (2) Inhalation anthrax;
[0054] (3) Mixed anthrax.
[0055] See also Figure 1 , the skin anthrax detection method is as follows:
[0056] A1. Gram staining and skin lesion culture, plus blood culture, to determine whether the casualty has been attacked by cutaneous anthrax;
[0057] A2. Once eschar is present on the skin or the test result in step A1 is positive, the casualty shall be given antimicrobial treatment;
[0058] A3: If the culture in step A1 is negative and the papule has not progressed to eschar, cutaneous anthrax is unlikely.
[0059] A4. However, if the casualty is known or suspected to have been aerosol exposed to B. anthracis, inhalation anthrax prophylaxis should be continued for 60 days.
[0060] theory:
[0061] Local contact with anthrax spores can cause cutaneous anthrax, especially in areas with previous wounds or abrasions. Cutaneous anthrax is relatively easy to detect, and is typically characterized by the formation of a characteristic black eschar on the skin. The initial manifestation of cutaneous anthrax is a painless papule similar to that caused by mosquito bites. The painless papule usually occurs 1-12 days after contact with the spores, followed by blister bleeding, turbidity, depression, accompanied by necrosis and ulceration. A 1 to 5 cm black eschar forms above the ulcer, surrounded by many centimeters of edema and erythema. Because the characteristics of cutaneous anthrax are obvious, cutaneous anthrax is relatively easy to identify;
[0062] See also Figure 2-3 , the inhalation anthrax detection method is as follows:
[0063] S1. Group the injured according to whether they have symptoms;
[0064] S2. The injured patients will be further isolated in groups to prevent cross infection;
[0065] S3, grouping the injured persons isolated in step S2;
[0066] S4, dividing the groups in step S3 into two groups: those who need to be sent to the hospital for further examination, and those who need to take preventive antibiotics at home and wait for follow-up guidance;
[0067] S5. Further testing is performed on the two groups of injured persons in step S4 through medical institutions.
[0068] Symptoms in step S1 include the presence or absence of headache, neurological symptoms, fever, cough, dyspnea, nausea or vomiting, abnormal lung examination, rhinorrhea or sore throat;
[0069] Step S5 detection includes the following steps:
[0070] S101. First, check whether the high-risk casualties with a history of exposure have non-specific symptoms of the first stage;
[0071] S102. If no symptoms occur, continue to observe. If exposure is confirmed and asymptomatic, perform antimicrobial prophylaxis;
[0072] S103. If the first stage symptoms occur, the injured person shall be examined by white blood cell count, chest radiograph, blood culture, CT, etc.;
[0073] S104. According to the examination results, the injured are divided into two groups: one with normal examination results and one with abnormal examination results, and different treatment measures are taken for the two groups of injured;
[0074] theory:
[0075] Inhalation anthrax is the most common form of anthrax and can cause widespread casualties by releasing aerosols or anthrax spores. When a person inhales anthrax spores, they develop inhalation anthrax. Inhalation anthrax is considered the most deadly form of anthrax. Infection usually develops within a week of exposure but can last up to two months. Without treatment, only about 10-15% of people with inhalation anthrax survive. Early diagnosis of inhalation anthrax is difficult. The clinical presentation of inhalation anthrax occurs in two phases. Initially, symptoms are nonspecific, with malaise, unhelpful cough, and / or chest discomfort. In the second phase, respiratory distress, dyspnea, wheezing, and cyanosis develop suddenly. Necrotic edematous lymphadenitis develops in the tracheobronchial lymph nodes, and mediastinitis and pulmonary edema develop, with or without bloody pleural effusions;
[0076] See also Figure 3 , the hybrid anthrax detection method is as follows:
[0077] N1. Quantify the physiological indicators of the injured and divide them into three categories according to the values;
[0078] N2, the first page of examination can classify the casualty into three categories: those who need immediate IV Rx treatment, those who need PO Rx / PEP treatment, and those who need medical evaluation and symptom assessment;
[0079] N3. Use the second page of the form for the injured who need medical evaluation according to step N2;
[0080] N4. The table on page 2 classifies the casualties into three categories: those who need IVRx treatment, those who need PORx / PEP treatment, and those who need diagnostic testing, based on whether the casualties have anthrax symptoms.
[0081] N5, Screening Checklist combines easily collected vital sign data with brief questions about psychological function and symptoms, and is based on physical examination with observation of skin lesions, auscultation of the lungs, and assessment of ascites;
[0082] In step N4, the diagnostic testing includes ultrasound, radiography, and / or computed tomography of the chest and / or abdomen, or Gram stain or culture of pleural fluid, ascites, cerebrospinal fluid, or wound or blood culture, or polymerase chain reaction serology of clinical specimens in a sterile location, or other FDA-approved method for identification of Bacillus anthracis.
[0083] Although the present invention has been described above with reference to the embodiments, various modifications may be made thereto and parts thereof may be replaced by equivalents without departing from the scope of the present invention. In particular, as long as there is no structural conflict, the various features in the embodiments disclosed in the present invention may be used in combination with each other in any manner, and the fact that these combinations are not exhaustively described in this specification is only for the sake of omitting space and saving resources. Therefore, the present invention is not limited to the specific embodiments disclosed herein, but includes all technical solutions falling within the scope of the claims.
Claims
1. A method for detecting anthrax infection, characterized in that: Includes three tests for anthrax infection: (1) Cutaneous anthrax: (2) Inhalation anthrax; (3) Mixed anthrax.
2. A method for detecting anthrax infection according to claim 1, characterized in that: The skin anthrax detection method is as follows: A1. Gram staining and skin lesion culture, plus blood culture, to determine whether the casualty has been attacked by cutaneous anthrax; A2. Once eschar is present on the skin or the test result in step A1 is positive, the casualty shall be given antimicrobial treatment; A3: If the culture in step A1 is negative and the papule has not progressed to eschar, cutaneous anthrax is unlikely. A4. However, if the casualty is known or suspected to have been aerosol exposed to B. anthracis, inhalation anthrax prophylaxis should be continued for 60 days.
3. A method for detecting anthrax infection according to claim 1, characterized in that: The inhalation anthrax detection method is as follows: S1. Group the injured according to whether they have symptoms; S2. The injured patients will be further isolated in groups to prevent cross infection; S3, grouping the injured persons isolated in step S2; S4, dividing the groups in step S3 into two groups: those who need to be sent to the hospital for further examination, and those who need to take preventive antibiotics at home and wait for follow-up guidance; S5. Further testing is performed on the two groups of injured persons in step S4 through medical institutions.
4. A method for detecting anthrax infection according to claim 3, characterized in that: The symptoms in step S1 include headache, neurological symptoms, fever, cough, dyspnea, nausea or vomiting, abnormal lung examination, rhinorrhoea or sore throat, etc.
5. The method for detecting anthrax infection according to claim 1, characterized in that: The hybrid anthrax detection method is as follows: N1. Quantify the physiological indicators of the injured and divide them into three categories according to the values; N2, the first page of examination can classify the casualty into three categories: those who need immediate IV Rx treatment, those who need PO Rx / PEP treatment, and those who need medical evaluation and symptom assessment; N3. Use the second page of the form for the injured who need medical evaluation according to step N2; N4. The table on page 2 classifies the casualties into three categories: those who need IVRx treatment, those who need PORx / PEP treatment, and those who need diagnostic testing, based on whether the casualties have anthrax symptoms. N5. The screening checklist combines easily collected vital sign data with brief questions about psychological function and symptoms, and is based on a physical examination consisting of observation of skin lesions, auscultation of the lungs, and assessment of ascites.
6. A method for detecting anthrax infection according to claim 3, characterized in that: The step S5 detection includes the following steps: S101. First, check whether the high-risk casualties with a history of exposure have non-specific symptoms of the first stage; S102. If no symptoms occur, continue to observe. If exposure is confirmed and asymptomatic, perform antimicrobial prophylaxis; S103. If the first stage symptoms occur, the injured person shall be examined by white blood cell count, chest radiograph, blood culture, CT, etc.; S104. According to the examination results, the injured are divided into two groups: one with normal examination results and one with abnormal examination results, and different treatment measures are taken for the two groups of injured.
7. A method for detecting anthrax infection according to claim 5, characterized in that: In step N4, the diagnostic test includes ultrasound, radiography and / or computed tomography of the chest and / or abdomen, or Gram stain or culture of pleural effusion, ascites, cerebrospinal fluid or wound or blood culture, or polymerase chain reaction serology of clinical specimens in a sterile location, or other Food and Drug Administration approved methods for identification of Bacillus anthracis.
